This New York Times (NYT) editorial lays out the tension in the current debate over the very expensive (@$84,000/treatment un-discounted) Hepatitis C drugs: broad coverage that will significantly increase health plan costs or restricted coverage to keep costs under control but that will not benefit as many patients.
In the end, the NYT points out that manufacturers generally pay what the market will bear so calls for public and private insurers to push for lower pricing, which can support providing these drugs to more people.
MBGH is kicking off a specialty pharmacy management initiative for members which addresses this very issue. The initiative provides hands-on training, data analysis and, most importantly, technical assistance and consulting, that employers need to actually achieve cost savings in specialty spend while still making these drugs accessible to their employees and families. Contact Cristie Travis at email@example.com for more information.
Read the editorial